15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 6 firms covering DaVita HealthCare Partners Inc, 2 rate it Buy or better, 3 sit at Hold, and 1 rate it Sell or worse, a hold consensus. Targets span $140.00 to $270.00, a moderate spread. The average target of $216.50 sits 10% below the current $239.43. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 1 to 2 over recent months. On the fundamentals, the Street sees consensus EPS building from about $3.92 next quarter toward $17.22 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 ratings
Hold
Strong Buy00%
Buy233%
Hold350%
Sell117%
Strong Sell00%
Based on 6 analysts giving stock ratings to DaVita HealthCare Partners Inc.
As of Jul, 2 of 6 firms rate DVA a Buy (3 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
DVA EPS & revenue forecast
EPS · NEXT QUARTER
$3.92
Range $3.77 – $4.33 · 6 analysts · +56% YoY
Next period, 6 analysts expect DaVita HealthCare Partners Inc to earn $3.92 a share (range $3.77 – $4.33), versus $2.51 a year earlier. Full-year consensus is $14.83, growing to $17.22 the year after.
REVENUE · NEXT QUARTER
$3.5B
Range $3.5B – $3.6B · 6 analysts · +3% YoY
Revenue is expected to reach $3.5B (range $3.5B – $3.6B), +3.4% year-over-year. Full-year consensus is $14.1B, rising to $14.6B next year.
Top analysts covering DaVita HealthCare Partners Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on DVA.
#1
DM
David Macdonald
Truist Securities · Rank #67
Hold
$250.00+4.4% to target
Overall win rate
51%
+ Follow
#2
Andrew Mok
Barclays
Hold
$218.00-9.0% to target
Coverage
—
+ Follow
#3
Kevin Fischbeck
B of A Securities
Sell
No targeton DVA
Coverage
—
+ Follow
#4
AR
A.J. Rice
UBS
Buy
$270.00+12.8% to target
Coverage
—
+ Follow
#5
Ryan Langston
TD Cowen
Hold
$201.00-16.1% to target
Coverage
—
+ Follow
DVA stock forecast FAQ
What is DVA's average 12-month price target?+
The 6 analysts with a live target average $216.50 for DaVita HealthCare Partners Inc over the next 12 months, ranging from a $270.00 high to a $140.00 low.
Is DVA stock a Buy, Sell or Hold right now?+
The current consensus is Hold. Of the 6 analyst ratings, 2 are Buy or Strong Buy, 3 are Hold, and 1 are Sell or Strong Sell.
What are the highest and lowest price targets for DVA?+
The Street-high target is $270.00 (UBS), and the Street-low is $140.00 (B of A Securities). The average of all 6 active targets is $216.50.
How many Wall Street analysts cover DVA?+
6 analysts have an active rating on DaVita HealthCare Partners Inc, and 6 firms carry a live 12-month price target.
Who is the most accurate analyst covering DVA?+
Among analysts who currently cover DVA, David Macdonald of Truist Securities has the strongest overall Quantellect track record (Rank #67). Their current call is Hold with a $250.00 target.
What is DaVita HealthCare Partners Inc's projected EPS for next quarter?+
The consensus estimate is $3.92 per share (range $3.77 – $4.33) across 6 analysts. Full-year EPS is projected at $14.83, rising to $17.22 the following year.
How much revenue is DaVita HealthCare Partners Inc expected to report next quarter?+
Consensus revenue is $3.5B (range $3.5B – $3.6B). Full-year revenue is projected at $14.1B, growing to $14.6B next year.
Have analysts been upgrading or downgrading DVA lately?+
As of Jul, 2 of 6 firms rate DVA a Buy (3 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their DVA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
